As the Ebola outbreak in the Democratic Republic of the Congo (DRC) grew by six cases today, early data show that mAB114, a monoclonal antibody treatment for the disease, is safe and well-tolerated in adults, according to the results from the first human trial of the drug published today in The Lancet.